Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900328 | 1.00 | S100A4 (0.42) | S100A4TRPV1S1PR4PTPN1MASP2 | |
| SCHEMBL30062398 | 0.81 | HSPB1 (0.56) | HSPB1LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL397137 | 0.81 | HSPB1 (0.56) | HSPB1LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL1275605 | 0.81 | HSPB1 (0.51) | PTPN1HSPB1LMNAGAAMAPT | |
| SCHEMBL16959020 | 0.80 | PTPN1 (0.40) | PTPN1MASP2F2HSPB1ALDH1A1 | |
| SCHEMBL29839233 | 0.80 | ALDH1A1 (0.53) | PTPN1MASP2F2HSPB1ALDH1A1 | |
| SCHEMBL1130254 | 0.80 | ALDH1A1 (0.53) | PTPN1MASP2F2HSPB1ALDH1A1 | |
| SCHEMBL14553797 | 0.80 | TSHR (0.55) | S1PR4LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL1274774 | 0.80 | PDE7A (0.54) | S1PR4P2RY6LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL25626649 | 0.80 | S1PR4 (0.45) | S100A4TRPV1S1PR4MASP2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024051717-A1 | COMPOUND AS PLK1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117658987-A | Compounds as PLK1 inhibitors, and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-3150592-B1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-110746424-A | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| CN-105294654-B | ALK kinase inhibitors and its preparation method and application | 北京浦润奥生物科技有限责任公司 | 2018-01-09 | — | — | CN | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| CN-101450891-B | Preparation method of 2-fluoro-4-bromotrifluoromethoxybenzene | BINHAI KANGJIE CHEMICAL CO LTD | 2012-05-23 | — | — | CN | disclosed |
| CN-102245609-A | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2011-11-16 | — | — | CN | disclosed |
| EP-2350081-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| WO-2010042699-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| CN-101450891-A | Method for preparing 2-fluoro-4-bromo trifluoromethoxyphenyl | BINHAI KANGJIE CHEMICAL CO LTD (CN) | 2009-06-10 | — | — | CN | disclosed |
| WO-2001077062-A1 | METHOD FOR PRODUCING 4-BROMO- AND 4-CHLORO-2-NITRO-1-TRIFLUOROMETHOXYBENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-18 | — | — | WO | disclosed |
| US-4876376-A | Process for the halogenation, nitration and fluorination of aromatic derivatives | RHONE-POULENC SPECIALISTES CHIMIQUES (FR) | 1989-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | S100A4 4050/4885TRPV1 4842/4885S1PR4 2788/4885 |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | ALK, BRAF, ABL1 | S100A4 4045/4885TRPV1 4015/4885S1PR4 615/4885 |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | S100A4 3568/4885TRPV1 4257/4885S1PR4 3704/4885 |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | S100A4 3568/4885TRPV1 4257/4885S1PR4 3704/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | S100A4 3260/4885TRPV1 2597/4885S1PR4 4126/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | S100A4 3260/4885TRPV1 2597/4885S1PR4 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.